Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Novartis And Aventis Begin Merger Talks; Sanofi Considers Raising Bid

Executive Summary

Sanofi will continue to evaluate the market response to its tender offer for Aventis before deciding whether to sweeten its bid, CFO Marie-Helene Laimay said during a first quarter investor call April 22

You may also be interested in...

Sanofi-Aventis Deal Means More Leverage With Managed Care

Sanofi's $65 bil. merger with Aventis will offer the combined entity additional negotiating clout with large U.S. drug purchasers, Exec VP-Operations Hanspeter Spek said during an April 26 conference call

Novartis Misses Out On Another Merger, But Forces Sanofi To Pay More

Novartis will need to start over in its search for a merger partner after bowing out of the bidding process for Aventis

Sanofi Wins Aventis With $8 Bil. In Cash And Nominal Joint Control

Sanofi's winning bid for Aventis includes an additional $8 bil. in cash, nominal joint control of the merged company, and an acknowledgment of Aventis' Franco-German heritage

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts